KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBITDA Margin: 2011-2024

Historic EBITDA Margin for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -15.57%.

  • Esperion Therapeutics' EBITDA Margin rose 2129.00% to -35.89% in Q3 2025 from the same period last year, while for Sep 2025 it was -34.84%, marking a year-over-year decrease of 547.00%. This contributed to the annual value of -15.57% for FY2024, which is 16430.00% up from last year.
  • As of FY2024, Esperion Therapeutics' EBITDA Margin stood at -15.57%, which was up 91.34% from -179.87% recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' EBITDA Margin ranged from a high of -15.57% in FY2024 and a low of -343.08% during FY2021.
  • Moreover, its 3-year median value for EBITDA Margin was -179.87% (2023), whereas its average is -168.33%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 27,999bps in 2021, then soared by 16,430bps in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' EBITDA Margin stood at -63.10% in 2020, then crashed by 27,999bps to -343.08% in 2021, then surged by 3,354bps to -309.55% in 2022, then spiked by 12,968bps to -179.87% in 2023, then surged by 16,430bps to -15.57% in 2024.